



RESEARCH ARTICLE

A Novel and Efficient Synthesis of Various 7-Hydroxy-9(Furo[2,3-b]Quinolin-2-Yl)6H- Benzo[c]Coumarins and Evaluation of their Antimicrobial Activity

Dharati S. Patel, D. I. Brahmhatt*

Department of Chemistry, Sardar Patel University, Vallabh Vidyanagar-388120, Gujarat, India.

Manuscript No: IJPRS/V6/I1/00017, Received On: 21/02/2017, Accepted On: 24/02/2017

ABSTRACT

A series of novel 7-hydroxy-9-(furo[2,3-*b*]quinolin-2-yl)6*H*-benzo[*c*]coumarins (**3a-l**) has been synthesized by reacting various 3-coumarinoyl methyl pyridinium bromide salts (**1a-d**) with appropriate 2-acetyl-furo[2,3-*b*]quinoline (**2a-c**) in the presence of sodium acetate in refluxing acetic acid. All the synthesized compounds were characterized by IR, ¹H-NMR, ¹³C-APT and mass spectral analysis. All the synthesized compounds have been screened for their *invitro* anti-bacterial and anti-fungal activities. Some of the compounds have been found to be active against some bacterial and fungal pathogens compared to standard drugs. Among the synthesized derivatives, compounds **3c**, **3d**, **3f** and **3j** were found to be most efficient members of the series.

KEYWORDS

Furo[2,3-*b*]quinoline, benzo[*c*]coumarin, antimicrobial activity, broth dilution method

INTRODUCTION

Benzo[*c*]coumarins form an important class of coumarin derivatives and isolated from plant and animal sources and are mainly metabolic products of microorganisms¹⁻². Many benzo[*c*]coumarin derivatives are isolated as natural products and are synthesized in laboratories as well. Alternariol³ and its related derivatives like Autumnariol, Autumnariniol⁴ and Altenuisol⁵ are toxic secondary metabolites of various *Alternaria* fungi. Gilvocarcin⁶, Ravidomycin⁷ and Chrysomycins⁸ are *c*-glycoside antibiotics. They are isolated from various strains of streptomyces species. Arnottin⁹ and Defucogilvocarcin¹⁰ are natural products of the class of Gilvocarcine family and possess an antitumor activity¹¹.

Many benzo[*c*]coumarin derivatives are reported to possess various biological activities like antibiotic¹², anticancer¹³, antiviral¹⁴, anti-mutagenic¹⁵, anti-proliferative¹⁶, anti-allergic¹⁷, cytotoxic¹⁸ antioxidant¹⁹ etc. A literature survey for the synthesis of benzo[*c*]coumarins revealed that in majority of the reports on the synthesis of benzo[*c*]coumarins, the compounds have been synthesized by the lactonization of appropriately substituted biphenyl derivatives²⁰⁻²³. In the present work we have synthesized some new benzo[*c*]coumarin derivatives utilizing a novel and distinct approach.

Moreover, furoquinoline alkaloids are a group of alkaloids with simple structures. The simplest member of this group is dictamnine and most widespread member is skimianine. These alkaloids were found to possess wide range of biological activities such as anti-allergic, anti-inflammatory, cytotoxic and antiplatelet aggregation²⁴⁻²⁷.

***Address for Correspondence:**

Dr. Dinker I. Brahmhatt,

Department of Chemistry, Sardar Patel University,
Vallabh Vidyanagar-388120, Gujarat, India.

E-Mail Id: drdib317@gmail.com

Thus considering the importance of furoquinoline derivatives it was thought worthwhile to incorporate this moiety in benzo[*c*]coumarin as a substituent group and therefore in the present work synthesis of various 9-(furo[2,3-*b*]quinolin-2-yl)-7-hydroxy-6*H*-benzo[*c*]coumarins has been carried out.

MATERIALS AND METHOD

Experimental

All the melting points are uncorrected. All reactions were performed with commercially available reagents and they were used without further purification. Organic solvents were purified by standard methods and stored over molecular sieves. All the IR spectra (KBr disc) were recorded on Shimadzu FT-IR 8400-S spectrometer. ¹H NMR and ¹³C NMR spectra were recorded on Bruker Advance400 spectrometer operating at 400 MHz for ¹H NMR and 100 MHz for ¹³C NMR. The chemical shift (δ) is reported in ppm using chloroform-*d* as a solvent and calibrated standard solvent signal. Mass spectra were recorded on Shimadzu QP 2010 spectrometer. Column chromatography was performed with silica gel 60–120 mesh (Merck, Mumbai, India.). All the compounds were routinely checked for completion of the reaction on silica gel 60 F254 TLC plates and their spots were visualized by exposure to a UV lamp, iodine vapour or KMnO₄ reagents. Compounds 3-coumarinoyl methyl pyridinium bromide salt (**1a-d**)²⁸⁻³¹ was prepared according to literature procedure.

Preparation of 2-acetyl-furo[2,3-*b*]quinolines(**2a-c**):

The following general procedure was used. In a 250 mL round bottom flask equipped with a condenser, a mixture of an appropriate 2-hydroxy-3-formyl-quinoline (0.1mol), chloroacetone (0.1mol), dimethylformamide (90mL) was taken. To this anhydrous potassium carbonate (0.1 mol) was added and the reaction mixture was stirred for two hours at room temperature. Then after the reaction mixture was refluxed for 8 hours. It was allowed to come to room temperature. The solid obtained was

filtered out and washed with cold water. It was recrystallized from chloroform-hexane to white crystals.

2-Acetyl-furo[2,3-*b*]quinoline (2a): R₃ = H, yield = 76% ; mp 115°C; Anal. Calcd. For C₁₃H₉NO₂: C, 73.92; H, 4.29; N, 6.63%. Found: C, 73.85; H, 4.14; N, 6.21%. IR (KBr, ν_{\max} , cm⁻¹); 1615 (C=O stretching), 1485 and 1541 (aromatic C=C and C=N stretchings), 2927 (aliphatic C-H stretching), 3041 (aromatic C-H stretching).¹H NMR (400MHz, CDCl₃, δ): 2.56(3H, singlet, CH₃), 7.71-8.39 (6H, multiplet, aromatic protons).

6-Methyl-2-acetyl furo[2,3-*b*]quinoline(2b): R₃ = CH₃, Yield: 60%, mp 112 °C (lit³². mp 110°C)

6-Chloro-2-acetyl-furo[2,3-*b*]quinoline (2c): R₃ = Cl, yield = 75% ; mp 135-137°C; Anal. Calcd. For C₁₃H₈NO₂: C, 63.56; H, 3.28; N, 5.70%. Found: C, 63.48; H, 3.16; N, 5.65 %. IR (KBr, ν_{\max} , cm⁻¹); 1619 (C=O stretching), 1479 and 1538 (aromatic C=C and C=N stretchings), 2921(aliphatic C-H stretching), 3045 (aromatic C-H stretching).¹H NMR (400MHz, CDCl₃, δ): 2.68(3H, singlet, CH₃), 7.45-8.35 (5H, multiplet, aromatic protons)

General procedure for the synthesis of 7-hydroxy-9-(furo[2,3-*b*]quinolin-2-yl)-6*H*-benzo[*c*]coumarins (**3a-l**):

In a 100 mL three necked round bottom flask equipped with a dropping funnel, condenser, guard tube and magnetic needle, a solution of an appropriate 3-coumarinoyl methyl pyridinium bromide salt (**1a-d**) (0.004 mol) was taken in a glacial acetic acid (15 mL). To this, sodium acetate (0.012 mol) was added with stirring. Then, appropriate 2-acetyl-furo[2,3-*b*]quinoline (**2a-c**) in glacial acetic acid (10 mL) was added with stirring at room temperature during 10 minutes. The reaction mixture was further stirred for 20 minutes at room temperature and then refluxed for 8 hours. It was then allowed to cool to room temperature and poured into cold water (75 mL). The crude solid obtained was then extracted with chloroform (3 x 30 mL). The combined chloroform extract was washed with water (3 x 20 mL). It was dried over anhydrous

sodium sulfate. The removal of chloroform under reduced pressure gave a solid product. This was purified by column chromatography using silica gel and chloroform-petroleum ether (60-80) (6:4) as an eluent. Thus, 9-(furo[2,3-b]quinolin-2-yl)-7-hydroxy-6H-benzo[c]coumarins **3a-l** were obtained as yellow colored solid, which were recrystallized from chloroform-hexane.

Analytical and Spectral Characterization

The structure of all the synthesized (**3a-l**) compounds were confirmed by elemental analysis and IR, ¹H-NMR, ¹³C-NMR, and representative mass spectral data.

7-Hydroxy-9-(furo[2,3-b]quinolin-2-yl)-6H-benzo[c]coumarin (3a): White solid; yield = 64% ; mp 260-262°C; Anal. Calcd. For C₂₄H₁₃NO₄: C, 75.98; H, 3.45; N, 3.69%. Found: C, 75.95; H, 3.45; N, 3.69%. IR (KBr, ν_{max}, cm⁻¹); 1672(C=O stretching of δ-lactone of coumarin), 1609 (aromatic C=C stretching), 3104(aromatic C-H stretching), 3436 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ) : 7.24-8.51 (11H, multiplet, aromatic protons), 10.24(1H, singlet, C₄'), 12.26(1H, singlet, -OH proton). ¹³C NMR (100MHz, CDCl₃, δ) : 106.39(CH), 111.46(CH), 114.48(CH), 120.16(CH), 121.08(C), 122.45(CH), 123.96(C), 125.07(C), 126.61(CH), 128.31(CH), 129.43(CH), 130.07(C), 131.14(CH), 132.45(CH), 137.06(CH), 137.61(C), 145.20(C), 148.42(C), 150.03(CH), 151.77(C), 152.36(C), 161.10(C), 162.59(C) and 164.48(CO of coumarin).

7-Hydroxy-9-(6-methylfuro[2,3-b]quinolin-2-yl)-6H-benzo[c]coumarin (3b): White solid; yield = 60% ; mp 239-241°C; Anal. Calcd. For C₂₅H₁₅NO₄: C, 76.33; H, 3.84; N, 3.56%. Found: C, 76.31; H, 3.80; N, 3.52%. IR (KBr, ν_{max}, cm⁻¹); ν_{max} 1687 (C=O stretching of δ-lactone of coumarin), 1614 (aromatic C=C stretching), 3069 (aromatic C-H stretching), 2939 (aliphatic C-H stretching), 3403 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ): 2.50 (3H, s, CH₃), 7.24-8.54 (10H, m, Ar-H), 10.23(1H, s, C₄'), 12.20 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ) : 21.47(CH₃), 105.24(CH), 111.41(CH), 114.51(CH), 115.30(C), 119.84(CH), 121.33(C),

122.30(CH), 123.56(C), 123.91(C), 123.94(C), 125.54(CH), 128.62(CH), 131.49(CH), 132.59(CH), 136.73(CH), 141.52(C), 145.27(C), 149.45(C), 150.27(CH), 151.85(C), 161.03(C), 162.02(C), 162.63(C), 164.51(CO of coumarin).

7-Hydroxy-9-(6-chlorofuro[2,3-b]quinolin-2-yl)-6H-benzo[c]coumarin (3c): White solid; yield = 59% ; mp 220-221°C; Anal. Calcd. For C₂₄H₁₂ClNO₄: C, 69.66; H, 2.92; N, 3.38%. Found: C, 69.61; H, 2.89; N, 3.34%. IR (KBr, ν_{max}, cm⁻¹); ν_{max} 1686 (C=O stretching of δ-lactone of coumarin), 1617 (aromatic C=C stretching), 3063 (aromatic C-H stretching), 3409 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ) : 7.25-8.65 (10H, m, Ar-H), 10.12(1H, s, C₄'), 12.34 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ) : 106.34(CH), 111.36(CH), 114.42(CH), 118.12(CH), 121.21(C), 122.52(CH), 124.03(C), 125.14(C), 128.43(CH), 129.50(CH), 130.17(C), 131.22(CH), 132.42(CH), 137.09(CH), 139.64(C), 145.31(C), 148.61(C), 150.11(CH), 151.88(C), 152.48(C), 153.70(C), 161.22(C), 162.75(C), 163.99(CO of coumarin).

7-Hydroxy-4-methoxy-9-(furo[2,3-b]quinolin-2-yl)-6H-benzo[c]coumarin (3d): White solid; yield = 59% ; mp 167-168°C; Anal. Calcd. For C₂₅H₁₅NO₅: C, 73.35; H, 3.69; N, 3.42%. Found: C, 73.30; H, 3.71; N, 3.39%. IR (KBr, ν_{max}, cm⁻¹); ν_{max} 1671 (C=O stretching of δ-lactone of coumarin), 1615 (aromatic C=C stretching), 2920 (aliphatic C-H stretching), 3061 (aromatic C-H stretching), 3429 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ) : 3.56 (3H, s, OCH₃), 7.24-8.52 (10H, m, Ar-H), 10.26(1H, s, C₄'), 12.23 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ) : 55.36(OCH₃), 106.44(CH), 111.32(CH), 114.62(CH), 115.36(C), 120.03(CH), 121.49(C), 122.40(CH), 123.73(C), 123.77(C), 124.02(C), 125.01(CH), 128.68(CH), 131.61(CH), 136.85(CH), 141.52(C), 145.36(CH), 149.51(C), 150.34(CH), 151.93(C), 153.02(C), 160.98(C), 162.11(C), 164.62(CO of coumarin).

7-Hydroxy-4-methoxy-9-(6-methylfuro[2,3-b]quinolin-2-yl)-6H-benzo[c]coumarin (3e):

White solid; yield = 57% ; mp 169-171°C; Anal. Calcd. For C₂₆H₁₇NO₅: C, 73.75; H, 4.05; N, 3.31%. Found: C, 73.71; H, 4.01; N, 3.26%. IR (KBr, ν_{\max} , cm⁻¹); ν_{\max} 1680 (C=O stretching of δ -lactone of coumarin), 1609 (aromatic C=C stretching), 3064 (aromatic C-H stretching), 2922 (aliphatic C-H stretching), 3430 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ) : 2.31 (3H, s, CH₃), 3.35 (3H, s, OCH₃), 7.25-8.42 (9H, m, Ar-H), 10.23(1H, s, C₄'), 12.19 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ) : 23.35(CH₃), 55.73(OCH₃), 107.04(CH), 111.45(C), 115.17(C), 120.16(CH), 121.08(C), 122.44(CH), 123.95(C), 125.07(C), 126.62(CH), 128.31(CH), 129.43(CH), 130.07(C), 131.14(CH), 132.44(CH), 137.05(CH), 137.62(C), 145.20(C), 148.42(C), 150.03(CH), 151.77(C), 152.35(C), 161.10(C), 162.58(C) and 164.71(CO of coumarin)

7-Hydroxy-4-methoxy-9-(6-chlorofuro[2,3-b]quinolin-2-yl)-6H-benzo[c]coumarin (3f):

White solid; yield = 58% ; mp 180-182°C; Anal. Calcd. For C₂₅H₁₄ClNO₅: C, 67.65; H, 3.18; N, 3.16%. Found: C, 67.32; H, 3.21; N, 3.12%. IR (KBr, ν_{\max} , cm⁻¹); ν_{\max} 1683 (C=O stretching of δ -lactone of coumarin), 1624 (aromatic C=C stretching), 3090 (aromatic C-H stretching), 2920 (aliphatic C-H stretching), 3417 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ): 3.26 (3H, s, OCH₃), 7.24-8.51 (9H, m, Ar-H), 10.26(1H, s, C₄'-H), 12.23(1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ) : 55.49(OCH₃), 106.23(CH), 111.49(CH), 114.53(CH), 115.87(C), 118.31(CH), 122.55(CH), 122.68(C), 124.02(CH), 124.42(CH), 127.49(C), 129.50(CH), 134.98(C), 136.22(CH), 139.88(C), 141.16(C), 145.77(C), 148.13(C), 149.27(CH), 150.40(C), 153.58(C), 160.33(C), 161.28(C), 162.30(CO of coumarin).

2-Bromo-7-hydroxy-9-(furo[2,3-b]quinolin-2-yl)-6H-benzo[c]coumarin (3g):

White solid; yield = 55% ; mp 248-250°C; Anal. Calcd. For C₂₄H₁₂BrNO₄: C, 62.90; H, 2.64; N, 3.06%. Found: C, 62.85; H, 42.60; N, 3.01%. IR (KBr, ν_{\max} , cm⁻¹); ν_{\max} 1673 (C=O stretching of δ -

lactone of coumarin), 1616 (aromatic C=C stretching), 3077 (aromatic C-H stretching), 2918 (aliphatic C-H stretching), 3417 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ) : 7.60-9.06 (11H, m, Ar-H), 12.00 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ) : 106.42(CH), 110.31(C), 114.23(C), 115.21(C), 119.45(CH), 122.18(CH), 122.88(C), 124.21(CH), 124.23(CH), 125.66(C), 127.56(C), 127.79(CH), 129.85(CH), 132.53(CH), 133.96(C), 136.36(CH), 138.23(C), 141.73(C), 145.58(CH), 149.23(CH), 151.89(C), 153.58(C), 157.83 and 162.31(CO of coumarin)

2-Bromo-7-hydroxy-9-(6-methylfuro[2,3-b]quinolin-2-yl)6H-benzo[c]coumarin (3h):

White solid; yield = 59% ; mp 212-214°C; Anal. Calcd. For C₂₅H₁₄BrNO₄: C, 63.58; H, 2.99; N, 2.97%. Found: C, 63.52; H, 2.94; N, 2.99%. IR (KBr, ν_{\max} , cm⁻¹); ν_{\max} 1686 (C=O stretching of δ -lactone of coumarin), 1613 (aromatic C=C stretching), 3057 (aromatic C-H stretching), 2920 (aliphatic C-H stretching), 3419 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ) : 2.50 (3H, s, CH₃), 7.44-8.61 (9H, m, Ar-H), 12.26 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ) : 22.52(CH₃), 106.06(CH), 112.22(C), 114.52(C), 118.10(CH), 119.02(CH), 122.26(CH), 122.98(CH), 124.75(CH), 125.50(CH), 126.68(C), 128.60(C), 128.95(CH), 129.35(C), 132.44(C), 135.43(C), 141.52(C), 145.79(CH), 148.27(C), 149.08(CH), 151.81(C), 154.51(C), 155.09(C) and 164.27(CO of coumarin).

2-Bromo-7-hydroxy-9-(6-chlorofuro[2,3-b]quinolin-2-yl)6H-benzo[c]coumarin (3i):

White solid; yield = 60% ; mp 271-273°C; Anal. Calcd. For C₂₄H₁₁BrClNO₄: C, 58.50; H, 2.25; N, 2.84%. Found: C, 58.47; H, 2.28; N, 2.87%. IR (KBr, ν_{\max} , cm⁻¹); ν_{\max} 1688 (C=O stretching of δ -lactone of coumarin), 1611 (aromatic C=C stretching), 2952 (aliphatic C-H stretching), 3060 (aromatic C-H stretching), 3411 (O-H stretching) (D₂O exchangeable). ¹H NMR (400MHz, CDCl₃, δ) : 7.50-8.96 (9H, m, Ar-H), 12.25 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ) : 106.53(CH), 112.58(C), 114.13(CH), 119.35(CH), 122.79(C), 124.01(CH), 125.96(C), 127.15(C), 129.00(C), 129.60(CH), 131.48(C),

132.15(CH), 133.36(C), 135.35(C), 135.59(CH), 136.56(CH), 137.55(C), 145.62(CH), 147.72(C), 149.38(CH), 152.34(C), 153.56(C), 159.33(C), 163.17(CO of coumarin)

4-Hydroxy-2-(furo[2,3-b]quinolin-2-yl)-5H-dibenzo[c,f]coumarin (3j): White solid; yield = 58%; mp 223-225°C; Anal. Calcd. For C₂₈H₁₅NO₄: C, 78.31; H, 3.52; N, 3.26%. Found: C, 78.29; H, 3.50; N, 3.28%. IR (KBr, ν_{\max} , cm⁻¹); ν_{\max} 1683 (C=O stretching of δ -lactone of coumarin), 1614 (aromatic C=C stretching), 3080 (aromatic C-H stretching), 3440 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ): 7.59-9.31 (14H, m, aromatic protons), 11.36 (1H, singlet, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ): 118.02(CH), 119.13(CH), 119.35(CH), 120.11(CH), 120.84(C), 121.16(C), 121.34(CH), 122.06(CH), 122.60(CH), 123.18(CH), 124.38(C), 125.01(CH), 125.12(C), 125.18(CH), 127.48(CH), 128.75(C), 129.96(CH), 139.64(CH), 142.49(C), 142.99(C), 143.58(CH), 146.84(C), 147.80(C), 151.92(C), 152.56(C), 155.11(C), 155.27(C), 162.55(CO of coumarin)

4-Hydroxy-2-(6-methylfuro[2,3-b]quinolin-2-yl)-5H-dibenzo[c,f]coumarin (3k): White solid; yield = 61% ; mp 232-234°C; Anal. Calcd. For C₂₉H₁₇NO₄: C, 78.55; H, 3.86; N, 3.16%. Found: C, 78.51; H, 3.90; N, 3.14%. IR (KBr, ν_{\max} , cm⁻¹); ν_{\max} 1697 (C=O stretching of δ -lactone of coumarin), 1618 (aromatic C=C stretching), 3078 (aromatic C-H stretching), 2923 (aliphatic C-H stretching), 3420 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ): 2.50 (3H, s, CH₃), 7.52-9.38 (13H, m, Ar-H), 11.59 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ): 23.28(CH₃), 118.65(CH), 119.25(CH), 119.28(C), 119.48(C), 120.14(CH), 120.36(CH), 121.20(C), 122.46(CH), 123.19(C), 124.15(C), 124.46(CH), 124.81(CH), 125.40(C), 128.06(CH), 128.52(CH), 128.80(CH), 130.72(CH), 132.15(CH), 132.51(C), 135.85(C), 139.41(CH), 142.49(C), 143.12(CH), 146.94(C), 148.33(C), 154.01(C), 162.92 (CO of coumarin)

4-Hydroxy-2-(6-chlorofuro[2,3-b]quinolin-2-yl)-5H-dibenzo[c,f]coumarin (3l): White solid;

yield = 58%; mp 248-250°C; Anal. Calcd. For C₂₈H₁₄ClNO₄: C, 72.50; H, 3.04; N, 3.02%. Found: C, 72.48; H, 3.01; N, 3.12%. IR (KBr, ν_{\max} , cm⁻¹); ν_{\max} 1699 (C=O stretching of δ -lactone of coumarin), 1614 (aromatic C=C stretching), 3056 (aromatic C-H stretching), 3425 (O-H stretching). ¹H NMR (400MHz, CDCl₃, δ): 7.56-9.31 (13H, m, Ar-H), 11.36 (1H, s, -OH proton) (D₂O exchangeable). ¹³C NMR (100MHz, CDCl₃, δ): 118.02(CH), 119.12(CH), 119.18(C), 119.48(C), 120.49(CH), 120.75(CH), 121.64(C), 121.96(CH), 122.49(C), 123.99(C), 124.58(CH), 125.84(CH), 127.35(C), 127.35(CH), 128.84(CH), 129.11(CH), 129.34(CH), 139.16(CH), 142.06(C), 142.60(CH), 143.18(C), 146.38(C), 148.01(C), 150.92(C), 151.56(C), 156.11(C), 156.27(C), 162.55(CO of coumarin).


RESULTS AND DISCUSSION

Chemistry

With a view to synthesizing some new furoquinolinyl substituted benzo[c]coumarins adopting a new synthetic route, the present work was carried out. In the present work, various 7-hydroxy-9-(furo[2,3-b]quinolin-2-yl)6H-benzo[c]coumarins (**3a-l**) have been synthesized by reacting an appropriate 3-coumarinoyl methyl pyridinium bromide salt (**1a-d**) with 2-acetyl-furo[2,3-b]quinoline (**2a-c**) in the presence of sodium acetate in refluxing acetic acid. (**Scheme-1**). The structures of all the synthesized compounds (**3a-l**) were established by IR, ¹H-NMR, ¹³C-NMR and selected mass spectral data are shown in experimental section **2.2**.


Mechanism

It is reported that reaction of α,β -unsaturated ketone with methyl ketone or ketone with active methylene group in the presence of sodium acetate results in a formation of 1,3,5-trisubstituted benzene derivatives³³. This novel reaction is utilized in the preparation of present compounds. Here the benzene ring has been built up between 3 and 4 position of coumarin nucleus by utilizing this reaction. The plausible mechanism for the synthesis of target compounds (**3a-l**) is shown in **Scheme-2**.



Compound	R	R ₁	R ₂	R ₃	Compound	R	R ₁	R ₂	R ₃
3a	H	H	H	H	3g	H	Br	OCH ₃	H
3b	H	H	H	CH ₃	3h	H	Br	Cl	CH ₃
3c	H	H	H	Cl	3i	H	Br	H	Cl
3d	OCH ₃	H	H	H	3j	H	-Benzo-		H
3e	OCH ₃	H	H	CH ₃	3k	H		CH ₃	
3f	OCH ₃	H	H	Cl	3l	H		Cl	

Scheme-1: Synthetic scheme for the compounds (3a-1)



Scheme-2: Plausible mechanism for the synthesis of target compounds (3a-1)

The reaction proceeds by the anion generation from the acetyl group of compound (**2a-d**). This anion further adds to the 3,4-double bond of coumarin(**1a-c**) and results in the formation of intermediate (**A**) having 1,5-dione functionality. The active methylene group in (**A**) then gets cyclized with carbonyl group of furo[2,3-b]quinoline moiety resulting in the formation of intermediate (**B**) which finally gets converted into the product by loss of water molecule and subsequent aromatization. The reaction is smooth and results the furoquinolinyl substituted benzo[c]coumarins (**3a-l**) in good yield.

Biological Results

Antimicrobial Activity

The newly synthesized target compounds (**3a-l**) were evaluated for their *in vitro* antibacterial activity against two Gram positive bacteria *Staphylococcus aureus* (MTCC 96) and *Bacillus subtilis* (MTCC 441) and two Gram negative bacteria *Escherichia coli* (MTCC 443) and *Salmonella typhi* (MTCC 98). They were also evaluated for their *in vitro* antifungal activity against *Candida albicans* (MTCC 227) and *Aspergillus niger* (MTCC 282) as fungal strains. Broth dilution method was used for the determination of the antibacterial and antifungal activity as recommended by NCCLS³⁴. Ampicillin, Chloramphenicol and Norfloxacin were used as standard antibacterial drugs, whereas Griseofulvin and Nystatin were used as standard antifungal drugs. All MTCC cultures were collected from Institute of Microbial Technology, Chandigarh and tested against above mentioned known drugs. Mueller-Hinton broth was used as the nutrient medium for the test bacteria and Sabouraud Dextrose broth was used for the test fungi. Inoculum size for the test strains was adjusted to 10⁸ CFU (Colony Forming Unit per milliliter) per milliliter by comparing the turbidity. Each synthesized compound was diluted with DMSO so as to have the stock solution of 2000 µg/mL concentration as a stock solution. The results were recorded in the form of primary and secondary screening. The synthesized compounds (**3a-l**) were screened for their antibacterial and antifungal activity at

the concentration of 1000, 500 and 250 µg/mL for the primary screening. The synthesized compound showing activity against microbes in the primary screening were further screened in a second set of dilution at concentrations of 200, 100, 62.5, 50 and 25 µg/mL. The suspension of 10 µL from each well were further incubated and growth was noted at 37°C after 24 hour for bacteria and 48 hour for fungi. The lowest concentration which showed no visible growth (turbidity) after spot subculture was considered as the minimum inhibitory concentration (MIC) for each compound. The investigation of the data summarized in (**Table-1**) reveals that many compounds were found to be active against Gram-positive bacteria while some of the compounds were found to be active against Gram-negative bacterial and fungal species as compared to that of the standard antimicrobial drugs.

Antimicrobial Evaluation

The compounds (**3a-l**) were screened for their *invitro* antibacterial and antifungal evaluation against various bacterial and fungal pathogens by broth dilution method. Ampicillin, Chloramphenicol, Norfloxacin, Griseofulvin and Nystatin were used as standard drugs. The values of MIC are summarized in **Table-1**. Upon evaluating the antimicrobial activity data, it was observed that compound **3c**, **3h** and **3k** (MIC = 200µg/mL) showed good activity compared to Ampicillin (MIC = 250µg/mL) against gram positive bacteria *B. subtilis*. The Compounds **3b**, **3d**, **3e**, **3f**, **3g** and **3l** (MIC = 250µg/mL) exerted equipotent activity against gram positive bacteria *B. subtilis*. against *S. aureus*, Compounds **3j** and **3l** (MIC = 100µg/mL) and Compounds **3d**, **3e** and **3k** (MIC = 125µg/mL) exhibited moderate activity compared to Ampicillin (MIC = 250µg/mL) against gram positive bacteria *S. aureus*. Compounds **3b** and **3g** (MIC = 200µg/mL) showed better activity compared to Ampicillin (MIC = 250µg/mL) against gram positive bacteria *S. aureus*. Compounds **3a**, **3c**, **3h** and **3i** (MIC = 250µg/mL) were found equipotent to Ampicillin (MIC = 250µg/mL) against gram positive bacteria *S. aureus*.

Table 1: *In vitro* Antimicrobial activity of compounds (3a-l)

Compound	Minimum Inhibitory Concentration (MIC, $\mu\text{g/mL}^{-1}$)					
	Gram +ve bacteria		Gram -ve bacteria		Fungi	
	<i>B.s.</i>	<i>S.a.</i>	<i>E.c.</i>	<i>S.t.</i>	<i>A.n.</i>	<i>C.a.</i>
	MTCC4 41	MTCC96	MTCC443	MTCC98	MTCC2 82	MTCC22 7
3a	500	250	100	100	500	500
3b	250	200	500	250	200	500
3c	200	250	62.5	100	250	250
3d	250	125	62.5	100	500	1000
3e	250	125	200	250	500	1000
3f	250	500	100	62.5	1000	250
3g	250	200	100	200	1000	200
3h	200	250	100	200	500	250
3i	500	250	250	250	1000	200
3j	500	100	62.5	100	1000	>1000
3k	200	125	100	200	1000	1000
3l	250	100	200	250	>1000	1000
Ampicillin	250	250	100	100	-	-
Chlorampheni	50	50	50	50	-	-
Norfloxacin	100	10	10	10	-	-
Griseofulvin	-	-	-	-	100	500
Nystatin	-	-	-	-	100	100

Compounds **3c**, **3d**, **3f** and **3j** (MIC = $62.5\mu\text{g/mL}$) exhibited outstanding activity compared to Ampicillin (MIC = $100\mu\text{g/mL}$) against gram negative bacteria *E. coli* and *S. typhi* respectively. The compounds **3a**, **3f**, **3g**, **3h** and **3k** (MIC = $100\mu\text{g/mL}$) and compounds **3a**, **3c**, **3d**, and **3j** (MIC = $100\mu\text{g/mL}$) were found equipotent compared to Ampicillin (MIC = $100\mu\text{g/mL}$) against *E. coli* and *S. typhi* respectively. Compound **3i** and **3g** (MIC = $200\mu\text{g/mL}$) and compounds **3c**, **3f** and **3h** (MIC = $250\mu\text{g/mL}$) were found to be more active against *C. albicans* compared to Griseofulvin (MIC = $500\mu\text{g/mL}$). Compounds **3a** and **3b** (MIC = $500\mu\text{g/mL}$) were found equipotent to Griseofulvin (MIC = $500\mu\text{g/mL}$) against *C. albicans*.

It is perceived from the antimicrobial data that almost all the tested derivatives **3a-l** was found to be potent against the gram positive bacterial

strains. Among all the tested compounds, the compounds **3c**, **3d**, **3f** and **3j** were found to be more efficient members of the series.

Majority of the synthesized compounds were active against Gram-positive bacteria viz. *Bacillus subtilis* (MTCC 441) and *Staphylococcus aureus* (MTCC 96), Gram-negative bacteria viz. *Escherichia coli* (MTCC 443) and *Salmonella typhi* (MTCC 98). Some of the synthesized compounds were found sufficiently potent to inhibit fungal pathogen viz. *Candida albicans* (MTCC 227).

CONCLUSION

A novel and efficient protocol for the synthesis of a series of furoquinoliny substituted benzo[c]coumarin derivatives was described and the synthesized compounds were screened for their *in vitro* antimicrobial evaluation. The results indicated that all the synthesized compounds

shown good antibacterial activity. In particular, compounds **3c**, **3d**, **3f** and **3j** exhibited the more potent inhibitory activity against bacterial and fungal pathogens as compared to other compounds and emerged as potential lead compounds for further investigations.

ACKNOWLEDGEMENT

The authors are thankful to the Head, Department of Chemistry, Sardar Patel University for providing research facilities. Financial assistance to DSP from the UGC, New Delhi, India, is highly acknowledged.

REFERENCES

1. Shirataki, Y., & Toda, S. (2001). Antioxidative Effects of Dibenzo- α -pyrones in Fruits of *Trap a natans* on Lipid Peroxidation. *55*(5), 247-250.
2. Liang, D., Luo, H., Liu, Y. F., Hao, Z. Y., Wang, Y., Zhang, C. L., & Yu, D. Q. (2013). Lysilactones A–C, three 6H-dibenzo [b, d] pyran-6-one glycosides from *Lysimachia clethroides*, total synthesis of Lysilactone A. *Tetrahedron*, *69*(9), 2093-2097.
3. K Koch, J Podlech, M Metzler (2005). *Journal of Organic Chemistry*, *70*(8), 3275
4. Tamm, C. (1972). Die Homo-isoflavone, eine neue Klasse von Naturstoffen. *Arzneimittel-Forschung*, *22*, 1776-1784.
5. Pero, R. W., Harvan, D., & Blois, M. C. (1973). Isolation of the toxin, altenuisol, from the fungus, *alternariatenuis* auct. *Tetrahedron Letters*, *14*(12), 945-948.
6. Suzuki, K. (1994). Total synthesis of aryl C-glycoside antibiotics. *Pure and Applied Chemistry*, *66*(10-11), 2175-2178.
7. Stulík, K., Amatore, C., Holub, K., Marecek, V., & Kutner, W. (2000). Microelectrodes. Definitions, characterization, and applications (Technical report). *Pure and Applied Chemistry*, *72*(8), 1483-92.
8. Weiss, U., Yoshihira, K., Highet, R. J., & Wei, T. T. (1982). The Chemistry of the Antibiotics Chrysomycin A and B Antitumor Activity of Chrysomycin A. *The Journal of Antibiotics*, *35*(9), 1194-1201.
9. Madan, S., & Cheng, C. H. (2006). Nickel-catalyzed synthesis of benzocoumarins: Application to the total synthesis of arnottin I. *The Journal of Organic Chemistry*, *71*(21), 8312-8315.
10. Hart, D. J., & Mannino, A. (1996). Synthesis of defucogilvocarcin V isosteres via MAD-mediated conjugate addition of carbanions to naphthoquinone ketals. *Tetrahedron*, *52*(11), 3841-3856.
11. Hacksell, U., & Daves, G. D. (1985). 1 The Chemistry and Biochemistry of C-Nucleosides and C-Arylglycosides. *Progress in Medicinal Chemistry*, *22*, 1-65.
12. Morimoto, M., OKUBO, S., TOMITA, F., & MARUMO, H. (1981). Gilvocarcins, new antitumor antibiotics 3. Antitumor activity. *The Journal of Antibiotics*, *34*(6), 701-707.
13. Tomita, F., Takahashi, K. I., & Tamaoki, T. (1982). Gilvocarcins, new antitumor antibiotics. 4. Mode of action. *The Journal of Antibiotics*, *35*(8), 1038-1041.
14. Nakashima, H., Murakami, T., Yamamoto, N., Sakagami, H., Tanuma, S. I., Hatano, T., & Okuda, T. (1992). Inhibition of human immunodeficiency viral replication by tannins and related compounds. *Antiviral Research*, *18*(1), 91-103.
15. Hayatsu, H., Inada, N., Kakutani, T., Arimoto, S., Negishi, T., Mori, K., & Sakata, I. (1992). Suppression of genotoxicity of carcinogens by (-)-epigallocatechin gallate. *Preventive Medicine*, *21*(3), 370-376.
16. Qiu, Z., Zhou, B., Jin, L., Yu, H., Liu, Y., & Zhu, F. (2013). In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. *Food and Chemical Toxicology*, *59*, 428-437.
17. Sakurai, M., Nishio, M., Yamamoto, K., Okuda, T., & Ohnuki, T. (2003). TMC-264, a novel antiallergic heptaketide produced by the fungus *Phoma* sp. TC 1674. *Organic Letters*, *5*(7), 1083-1085.

18. Aly, A. H., Edrada-Ebel, R., Indriani, I. D., Wray, V., Müller, W. E., Totzke, F., & Proksch, P. (2008). Cytotoxic metabolites from the fungal endophyte *Alternaria* sp. and their subsequent detection in its host plant *Polygonum senegalense*. *Journal of Natural Products*, 71(6), 972-980.
19. Hormazabal, E., Astudillo, L., Rodríguez, J., & Theoduloz, C. (2005). Metabolites from *Microsphaeropsis olivacea*, an endophytic fungus of *Pilgerodendron uviferum*. *Zeitschrift für Naturforschung C*, 60(1-2), 11-21.
20. Song, Y. C., Huang, W. Y., Sun, C., Wang, F. W., & Tan, R. X. (2005). Characterization of graphislactone A as the antioxidant and free radical-scavenging substance from the culture of *Cephalosporium* sp. IFB-E001, an endophytic fungus in *Trachelospermum jasminoides*. *Biological and Pharmaceutical Bulletin*, 28(3), 506-509.
21. Appel, B., Saleh, N. N., & Langer, P. (2006). Domino Reactions of 1, 3-Bis-Silyl Enol Ethers with Benzopyrylium Triflates: Efficient Synthesis of Fluorescent 6H-Benzo [c] chromen-6-ones, Dibenzo [c, d] chromen-6-ones, and 2, 3-Dihydro-1H-4, 6-dioxachrysen-5-ones. *Chemistry—A European Journal*, 12(4), 1221-1236.
22. Alo, B. I., Kandil, A., Patil, P. A., Sharp, M. J., Siddiqui, M. A., Snieckus, V., & Josephy, P. D. (1991). Sequential directed ortho metalation-boronic acid cross-coupling reactions. A general regioselective route to oxygenated dibenzo [b, d] pyran-6-ones related to ellagic acid. *Journal of Organic Chemistry*, 56(12), 3763-3768.
23. Tremblay, M. S., & Sames, D. (2005). A new fluorogenic transformation: development of an optical probe for coenzyme Q. *Organic Letters*, 7(12), 2417-2420.
24. Huang, A. C., Lin, T. P., Kuo, S. C., & Wang, J. P. (1995). The antiallergic activities of synthetic acrophylline and acrophyllidine. *Journal of Natural Products*, 58(1), 117-120.
25. Chang, C. P., Lin, T. P., Wang, J. P., & Kuo, S. C. (2001). Synthesis and biological activity of N-substituted benzyl-6 (or7)-ethyl-2, 3, 4, 9-tetrahydrofuro [2, 3-b] quinolin-3, 4-diones. *Chinese Pharmaceutical Journal*, 53(5), 239-256.
26. Setzer, W. N., Setzer, M. C., Schmidt, J. M., Moriarity, D. M., Vogler, B., Reeb, S., & Haber, W. A. (2000). Cytotoxic components from the bark of *Stauranthus perforatus* from Monteverde, Costa Rica. *Planta Medica*, 66(05), 493-494.
27. Chen, K. S., Chang, Y. L., Teng, C. M., Chen, C. F., & Wu, Y. C. (2000). Furoquinolines with antiplatelet aggregation activity from leaves of *Melicope confusa*. *Planta Medica*, 66(01), 80-81.
28. Koelsch, C. F. (1950). Bromination of 3-acetocoumarin. *Journal of the American Chemical Society*, 72(7), 2993-2995.
29. T. V. P. Rao, V. R. Rao, *Indian Journal of Chemistry*, 25B (1986) 413-415.
30. Patel, A. A. (2011). Synthesis characterization and antimicrobial activity study of some heterocyclic substituted and heterocyclic fused coumarin derivatives.
31. Sashibala Singh, (1996). "Studies in coumarin and coumarin polymers", Sardar Patel University, Vallabh Vidyanagar.
32. Pramod N, Jayakumar Swami BHM, Kamat V, N Raj, Abdul Kadar M and S B Deva, (2011). *International Journal of chemical and pharmaceutical sciences*, 2(3), 9-14.
33. Eichinger, K., Nussbaumer, P., Balkan, S., & Schulz, G. (1987). Neue Synthesen alkylaryl-und diaryl-disubstituierter Phenole und Salicylsäure-ethylester. *Synthesis*, (12), 1061-1064.
34. Wayne, P. A. (2002). National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. M100-S12 NCCL.